\-\ Texto\\:\\ \ \(0\)\
\-\ nasal\\ mass\\ visible\\ on\\ right\\.\ \(0\)\
\-\ surgical\\ resection\\ followed\\ by\\ chemotherapy\ \(0\)\
\-\ enhancing\\ right\\-sided\\ nasal\\ mass\\ eroding\\ into\\ the\\ cribiform\\ fossa\\.\\ \\ there\\ are\\ associated\\ changes\\ of\\ both\\ acute\\ and\\ chronic\\ sinusitis\\.\ \(0\)\
\-\ esthesioneuroblastoma\ \(3\)\
\-\ \\â\\€\\¢\\ nasal\\ polyps\ \(0\)\
\-\ \\â\\€\\¢\\ squamous\\ cell\\ carcinoma\ \(1\)\
\-\ \\â\\€\\¢\\ inverting\\ papilloma\ \(1\)\
\-\ \\â\\€\\¢\\ esthesioneurblastoma\ \(0\)\
\-\ \\â\\€\\¢\\ neuroendocrine\\ tumor\ \(0\)\
\-\ 38\\ year\\ old\\ woman\\ with\\ 1\\ to\\ 2\\ year\\ history\\ of\\ intermittent\\ epistaxis\\.\\ \\ this\\ evaluation\\ is\\ for\\ symptoms\\ of\\ nasal\\ obstruction\\ and\\ imaging\\ was\\ done\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ nasal\\:\\ 0\\.5466200387729094\ \(0\)\
\-\ esthesioneurblastoma\\:\\ 0\\.2397128948717176\ \(0\)\
\-\ esthesioneuroblastoma\\:\\ 0\\.229058468394939\ \(0\)\
\-\ cribiform\\:\\ 0\\.2067939810767872\ \(0\)\
\-\ eroding\\:\\ 0\\.20328517014186376\ \(0\)\
\-\ inverting\\:\\ 0\\.19742161613018222\ \(0\)\
\-\ neuroendocrine\\:\\ 0\\.19491714587390846\ \(0\)\
\-\ epistaxis\\:\\ 0\\.1867671896534036\ \(0\)\
\-\ polyps\\:\\ 0\\.16165916867900817\ \(0\)\
\-\ sinusitis\\:\\ 0\\.15460998278265217\ \(0\)\
\-\ papilloma\\:\\ 0\\.13744734255200292\ \(0\)\
\-\ squamous\\:\\ 0\\.1348941659816741\ \(0\)\
\-\ 38\\:\\ 0\\.13301643529010637\ \(0\)\
\-\ visible\\:\\ 0\\.13212560255862285\ \(0\)\
\-\ intermittent\\:\\ 0\\.12251346196406865\ \(0\)\
\-\ done\\:\\ 0\\.119233480187076\ \(0\)\
\-\ fossa\\:\\ 0\\.11767200806100601\ \(0\)\
\-\ mass\\:\\ 0\\.11451089693972208\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.10643454865722414\ \(0\)\
\-\ obstruction\\:\\ 0\\.10499215341951083\ \(0\)\
\-\ followed\\:\\ 0\\.10122149114980676\ \(0\)\
\-\ right\\:\\ 0\\.09939202516342545\ \(0\)\
\-\ resection\\:\\ 0\\.09608390647611048\ \(0\)\
\-\ enhancing\\:\\ 0\\.09389955118742019\ \(0\)\
\-\ year\\:\\ 0\\.09238866556635654\ \(0\)\
\-\ evaluation\\:\\ 0\\.09141367756950881\ \(0\)\
\-\ changes\\:\\ 0\\.0905895910772447\ \(0\)\
\-\ carcinoma\\:\\ 0\\.08965972484308898\ \(0\)\
\-\ chronic\\:\\ 0\\.08897270403903998\ \(0\)\
\-\ of\\:\\ 0\\.08800068775132878\ \(0\)\
\-\ cell\\:\\ 0\\.08574618701036958\ \(0\)\
\-\ both\\:\\ 0\\.08358817199674554\ \(0\)\
\-\ symptoms\\:\\ 0\\.08201342259844657\ \(0\)\
\-\ acute\\:\\ 0\\.08108684098531263\ \(0\)\
\-\ into\\:\\ 0\\.07968098917259074\ \(0\)\
\-\ associated\\:\\ 0\\.07900529836631037\ \(0\)\
\-\ imaging\\:\\ 0\\.07877428985512627\ \(0\)\
\-\ tumor\\:\\ 0\\.07840317924810704\ \(0\)\
\-\ woman\\:\\ 0\\.07806520611425813\ \(0\)\
\-\ surgical\\:\\ 0\\.07285329964809766\ \(0\)\
\-\ by\\:\\ 0\\.06365362129610752\ \(0\)\
\-\ and\\:\\ 0\\.061947457074037385\ \(0\)\
\-\ there\\:\\ 0\\.0596422969116354\ \(0\)\
\-\ history\\:\\ 0\\.05726812738393541\ \(0\)\
\-\ are\\:\\ 0\\.056877898168664065\ \(0\)\
\-\ was\\:\\ 0\\.05223949003229206\ \(0\)\
\-\ this\\:\\ 0\\.05150622552575181\ \(0\)\
\-\ for\\:\\ 0\\.04543167492899123\ \(0\)\
\-\ on\\:\\ 0\\.045270514970224766\ \(0\)\
\-\ old\\:\\ 0\\.0443625500369751\ \(0\)\
\-\ is\\:\\ 0\\.04104944864336\ \(0\)\
\-\ to\\:\\ 0\\.03747316755309966\ \(0\)\
\-\ the\\:\\ 0\\.02990925402177627\ \(0\)\
\-\ with\\:\\ 0\\.029351089380430264\ \(0\)\
